Evogene Ltd. (NASDAQ:EVGN) traded sharply higher on Thursday after the company posted third-quarter results that topped profit expectations, even as revenue came in well below forecasts.

Shares of the computational chemistry and AI-driven small-molecule design firm rose 5.13% in premarket trading following the announcement.

For the quarter, Evogene reported a net loss of $0.31 per share, significantly better than analysts’ projected loss of $0.43. Revenue, however, totaled $310,000, missing estimates of $575,000 and falling sharply from $1.7 million a year ago. The company attributed the drop mainly to lower seed sales at its Casterra unit.

Evogene’s ongoing shift toward becoming a pure-play leader in computational chemistry—centered on generative small-molecule design for both pharma and agriculture—has begun to yield meaningful cost benefits. A cost-cutting program, largely completed by late Q2, reduced quarterly operating expenses to $2.9 million, compared with $6.6 million in the same period of 2024.

“Evogene is at a turning point – becoming a focused, AI-driven company built around our core engine, ChemPass AI,” said Mr. Ofer Haviv, President & CEO of Evogene. “This cutting-edge platform is redefining how small molecules are discovered and optimized, driving innovation across two global industries: pharma and agriculture.”

The company closed the quarter with roughly $16 million in cash and short-term deposits. That figure includes proceeds from its sale of Lavie Bio’s assets and the MicroBoost AI for Ag technology engine to ICL—transactions that contributed about $7.9 million in income during Q3.

For the first nine months of 2025, Evogene reported an operating loss of approximately $8.8 million, a sharp improvement from $15.3 million in the comparable period of 2024, largely reflecting lower expenses across its subsidiaries.

Evogene stock price

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.